By contrast, an American study based on 1401 prostate cancer and 1351 age-matched controls showed no association between hepsin SNPs or haplotypes and the risk of prostate cancer development, recurrence, or cancer death; thus, germline genetic variants of hepsin do not seem to contribute to the risk of prostate cancer and its prognosis [77]. This evidence concerns the gene HPN and prostate cancer.